{"nctId":"NCT01992523","briefTitle":"Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )","startDateStruct":{"date":"2013-11"},"conditions":["Acute Coronary Syndrome","Adverse Reaction to Antiplatelet Agent"],"count":82,"armGroups":[{"label":"Ticagrelor mashed pills","type":"EXPERIMENTAL","interventionNames":["Drug: Ticagrelor mashed pills"]},{"label":"Ticagrelor integral pills","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ticagrelor integral pills"]}],"interventions":[{"name":"Ticagrelor mashed pills","otherNames":[]},{"name":"Ticagrelor integral pills","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients presenting within 12 hours from the onset of symptoms with STEMI\n* Informed, written consent\n\nExclusion Criteria:\n\n* Age \\< 18 years or Age \\> 75 years\n* Active bleeding; bleeding diathesis; coagulopathy\n* Increased risk of bradycardiac events\n* History of gastrointestinal or genitourinary bleeding \\<2 months\n* Major surgery in the last 6 weeks\n* History of intracranial bleeding or structural abnormalities\n* Suspected aortic dissection\n* Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, known malignancies or other comorbid conditions with life expectancy \\<1 year)\n* Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux .\n* Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows\n* Known relevant hematological deviations: Hb \\<10 g/dl, Thrombi. \\<100x10\\^9/l\n* Use of coumadin derivatives within the last 7 days\n* Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine\n* Known severe liver disease, severe renal failure\n* Known allergy to the study medications\n* Pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Residual Platelet Reactivity","description":"residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]}]},{"type":"SECONDARY","title":"High Residual Platelet Reactivity","description":"The percent of patients with a high residual platelet reactivity (PRU \\> 208) 1 hour after ticagrelor LD.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Bleeding Events","description":"Percentage of participants with Major, minor, minimal bleeding (TIMI criteria) events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Dyspnoea and/or Symptomatic Bradycardia","description":"Percentage of participants with Occurrence of dyspnoea and/or symptomatic bradycardia","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Dyspnea","Serum creatinine increase","TIMI minor bleeding (TIMI criteria)","Ventricular pauses >= 3 sec"]}}}